Don deBethizy resigns as Targacept CEO
This article was originally published in Scrip
Targacept has announced management changes that include the surprising resignation of Dr Donald deBehizy, who is stepping down as president, CEO and a member of the board of directors. The search for a new CEO has already begun. In the meantime, the company will be led by a four-person office of the chairman, which will be led by Mark Skaletsky, Targacept's chair. The rest of the office of the chairman will comprise Jeffrey Brennan, senior vice-president of business and commercial development and CBO; Alan Musso, senior vice-president of finance and administration, CFO and treasurer; and Peter Zorn, senior vice-president of legal affairs, general counsel and secretary.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.